European Competitiveness Fund and Horizon programme (2028-2034; FP10)
A positive step from the European Parliament today on the future of research and innovation in Europe.
HLM4Rare welcomes the vote on 10 November in the ITRE Committee on the European Competitiveness Fund and the next Horizon programme (2028-2034; FP10). We particularly welcome the recognition of continued investment in health and biotechnology. Europe needs ambitious and dedicated investment in these fields to advance research and bring new solutions to people living with rare and complex diseases.
Supporting the rare disease community requires research and deployment to work together. FP10 aims to drive scientific discovery and early research, while the European Competitiveness Fund is needed to scale up solutions, support cross-border cooperation, and invest in health infrastructure across Member States. Linking these two programmes is what allows research to actually reach patients in clinical practice.
We are pleased to see European Reference Networks (ERNs) reflected in the ECF’s health priorities. Their inclusion is an important recognition of the role they play in strengthening cross-border cooperation and building more connected and resilient health systems across Europe by pooling expertise, knowledge and resources.
As discussions proceed between the European Parliament and the Council of the EU, this ambition must be preserved. ERNs connect research, innovation and access to care, pooling expertise across borders and helping turn scientific advances into benefits for patients. Investment at the level proposed by ITRE is the minimum required to keep these health infrastructures viable and ensure timely access to treatments and care for people living with rare and complex diseases.
This will also be part of the conversation at the HLM4Rare ’26 High-Level Meeting in Brussels from 1 to 3 December, where the rare disease community will come together to discuss how Europe can build on today’s momentum and ensure that research and innovation continue to deliver for patients.

